S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.
Weigang Tong,Hagop M. Kantarjian,Susan O'Brien,Stefan Faderl,Farhad Ravandi,William G. Wierda,Steven M. Kornblau,Gautam Borthakur,Guillermo Garcia-Manero,Elizabeth M. Burton,Mary Beth Rios,Jorge E. Cortes +11 more
TL;DR: Although patients with organ dysfunction treated with imatinib may have a higher rate of hematologic toxicity and require more frequent dose reductions, particularly when treated at higher doses, most patients can be adequately treated resulting in response rates similar to those without organ dysfunction.
Journal ArticleDOI
Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab
Deborah A. Thomas,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,William G. Wierda,Guillermo Garcia-Manero,Elias Jabbour,Alessandra Ferrajoli,Srdan Verstovsek,Jan A. Burger,Rebecca Garris,Jorge E. Romaguera,Fredrick B. Hagemeister,Hagop M. Kantarjian +13 more
TL;DR: The outcomes for Burkitt-type lymphoma/leukemia have improved significantly with the use of short, intensive, multi-agent chemotherapy regimens.
Journal ArticleDOI
Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)
Francesco Paolo Tambaro,Guillermo Garcia-Manero,Stefan Faderl,Susan O'Brien,Alessandra Ferrajoli,Jan A. Burger,Long Xuan Trinh,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating,William G. Wierda +10 more
TL;DR: There was no association between # of prior CLL regimens, karyotype category, or presence of CLL at AL Dx and survival from AL.
Journal ArticleDOI
Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.
Stefan Faderl,Deborah A. Thomas,Guillermo Garcia-Manero,Farhad Ravandi,Miloslav Beran,Michael Rytting,Charles Koller,Srdan Verstovsek,Gautam Borthakur,Michael Andreeff,Steve Kornblau,Khanh Vu,Rita Jarmon,Hagop M. Kantarjian +13 more
TL;DR: AHCVAD has activity in ALL salvage, however, asparaginase-related toxicities and neutropenic complications remain frequent and may limit the usefulness of this approach to selected patient populations.
Journal ArticleDOI
Modern treatment programs for adults with acute lymphoblastic leukemia
TL;DR: The development of techniques for identification and monitoring of minimal residual leukemia has provided possible ways to predict relapse and consider early intervention, and it is likely that therapeutic approaches and patient outcome will improve through the translation of biologic and molecular discoveries into effective and risk-adapted strategies.